ETC-216 - Phospholipid Therapy for Coronary Heart Disease (CHD) Patients

 

Key Data:

Drug (Brand/Generic)
ETC-216
Company/Licensee
Esperion Therapeutics / Pfizer
Therapy Class
Phospholipid
Product Description
Synthetic variant of HDL
Current Indication
Treatment of atherosclerosis
Market Sector
CVD
Development Status
Phase II



Home
New On This Site
Products & Services
Company A-Z
Industry Projects
Features
White Papers
Jobs & Careers
Industry News
Gallery
Events & Exhibitions
Newsletter
Advertise With Us
About Us
Client Area


RSS What is RSS
For every phase of your drug development